NAOV

NanoVibronix, Inc. (NAOV) | Rumor.io

NanoVibronix

NAOV

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.01

Market capitalization1.1M

Earnings per share-51.8

Dividend yield (TTM)—

Revenue (annual)2.6M

Net income (annual)-3.7M

Social

What share of all stock conversation is about NAOV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 25

NanoVibronix ($NAOV) surged 20.4% to $4.97 in afternoon trading.
The stock's volume was unusually low at 122,846, compared to the daily average of 988.5K.
Some investors are advising caution, suggesting that the stock may be a "trap" or that it has moved too quickly.

Generated by AI

Sentiment

Of the messages about NAOV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.36% +10.49
Bearish	—	—	—	5.64% -10.49

Bullish· Nov 25

NanoVibronix, Inc. ($NAOV) has shown significant price increases with a notable jump in volume, suggesting strong market interest.
The company's stock has been identified as a potential squeeze candidate, which could lead to a substantial price surge in the near future.
Investors are advised to buy $NAOV early, as it has the potential to triple in value, making it a lucrative opportunity for those who get in on time.

Bearish· Sep 15

The stock's recent price movements have been volatile, with some traders experiencing significant losses due to aggressive buying and selling.
Traders are concerned that the stock may be experiencing a "pump and dump" scenario, where it is being artificially inflated by promoters before being sold off at a loss.
The stock's technical analysis suggests that it is on a downtrend, with some traders predicting a significant price drop to around $17 by the end of the day.

Generated by AI

Topics

Of the messages about NAOV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	55.9%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	44.1%

Earnings· Aug 16

NanoVibronix, Inc. (NAOV) reported a significant improvement in quarterly earnings, with EPS rising from -$0.20 to -$0.01.
The company's quarterly earnings exceeded market expectations, with a beat of $0.09 EPS compared to the expected -$0.10 EPS.
NAOV's strong earnings were driven by revenue growth of 18% and a cash position of $6 million, with no long-term debt.

Announcements· Sep 15

NanoVibronix, Inc. (NAOV) announces the grant of a new U.S. patent, further expanding its ENvue Medical subsidiary's intellectual property portfolio.
The patent covers proprietary systems for guiding the insertion of medical devices, such as feeding tubes, using electromagnetic positioning technology, improving real-time visualization and procedural accuracy.
The new patent strengthens NanoVibronix's intellectual property portfolio and reinforces competitive barriers in its target markets, with the company's CEO calling it a "significant milestone".

Technical Analysis· Sep 15

$NAOV broke out with a bang, volume surged, and RSI hit the skies, painting a bullish picture.
$NAOV shattered expectations with a technical breakout, volume surged along with RSI signals, and the chart is now green.
$NAOV is holding above $15 after a sharp pullback from $17, reclaiming trend and flagging just above support with VWAP, with a strong support level at $12.00.

Generated by AI

Community

Of the messages about NAOV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	51.42%
Newcomers	—	—	—	48.58%

Regulars· Sep 18

NanoVibronix has launched the "Oscar" training aid to accelerate the adoption of its ENvue system, potentially unlocking new revenue opportunities.
The "Oscar" platform is expected to transform naso-enteral training, a medical technology breakthrough that could have a significant impact on the company's future.
The launch of "Oscar" is a strategic move to increase the adoption of ENvue, which could lead to increased revenue for NanoVibronix.

Newcomers· Oct 8

The target price for $NAOV is $7.50-8.50, with an estimated upside potential of 15%-25% due to patent approvals, financing news, and enhanced liquidity.
The recent share price increase in $NAOV is primarily driven by the U.S. patent approval received by its subsidiary, ENVue Medical, and has reached $7.31, with a 19.44% surge.
The low float of $NAOV, at 862k, may be fueling the after-hours run, but there are no major news catalysts visible, indicating potential volatility ahead.

Generated by AI

Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of IrelandTYLER, Texas, Aug. 18, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company, today announced a new exclusive distribution agreement with Peak Medical, a complete medical equipment solutions company, to expand commercial distribution of ENvue’s UroShield® device across the United Kingdom and Republic of I

1mo agoYahoo Finance

ENvue Medical completes US manufacturing transition

1mo agoInvesting.com

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

TYLER, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company, today announced it has completed the transition of its NanoVibronix manufacturing operations from Israel to the United States, and consolidated its research and development operations in Tel Aviv, Israel, supporting the Company’s broader initiative to reduce operating expenses and improve its cost structure. “Completing the transition of our Na

1mo agoYahoo Finance

Also Discussed

Investors talking about NAOV also mention

#	Name	Attention
1	Xenetic Biosciences, Inc.XBIO	0%new
2	Virpax Pharmaceuticals Inc.VRPX	0%0
3	CEMI - Chembio Diagnostics, Inc.	——
4	WHLM - Wilhelmina International, Inc.	——
5	WORX - SCWorx Corp.	——
6	MediaCo Holding Inc. Class A Common StockMDIA	0%0
7	Flora Growth Corp.FLGC	0%new
8	BeyondSpring Inc.BYSI	0%0
9	PRF Technologies Ltd.PRFX	0%+0
10	PharmaCyte Biotech, Inc.PMCB	0%0

NanoVibronix, Inc.

Healthcare
Medical Devices

NanoVibronix, Inc. is a healthcare equipment company specializing in the design, development, and marketing of medical devices that utilize proprietary low-intensity surface acoustic wave (SAW) technology. Its main focus is on non-invasive biological response-activating devices aimed at addressing key medical needs, particularly in pain therapy, biofilm prevention in medical catheters, and wound healing. Notable products include PainShield, a wearable patch delivering low-frequency ultrasound for drug-free pain management, and UroShield, an ultrasound actuator that attaches to catheters to reduce bacterial biofilm formation and lower the risk of catheter-associated infections. The company also has pipeline products targeting wound healing and potentially other therapeutic applications, all leveraging the core SAW platform. NanoVibronix outsources its manufacturing, while prioritizing research, regulatory compliance, and the development of distributor partnerships to expand its market reach. Established in 2003 and based in Texas, NanoVibronix serves hospitals, long-term care facilities, pain clinics, and individual patients worldwide, playing a significant role in advancing non-invasive therapies in the healthcare sector.

Website

Location

969 Pruitt Ave

Tyler, TX, 10523

United States

Social

What share of all stock conversation is about NAOV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 25

NanoVibronix ($NAOV) surged 20.4% to $4.97 in afternoon trading.
The stock's volume was unusually low at 122,846, compared to the daily average of 988.5K.
Some investors are advising caution, suggesting that the stock may be a "trap" or that it has moved too quickly.

Generated by AI

Sentiment

Of the messages about NAOV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.36% +10.49
Bearish	—	—	—	5.64% -10.49

Bullish· Nov 25

NanoVibronix, Inc. ($NAOV) has shown significant price increases with a notable jump in volume, suggesting strong market interest.
The company's stock has been identified as a potential squeeze candidate, which could lead to a substantial price surge in the near future.
Investors are advised to buy $NAOV early, as it has the potential to triple in value, making it a lucrative opportunity for those who get in on time.

Bearish· Sep 15

The stock's recent price movements have been volatile, with some traders experiencing significant losses due to aggressive buying and selling.
Traders are concerned that the stock may be experiencing a "pump and dump" scenario, where it is being artificially inflated by promoters before being sold off at a loss.
The stock's technical analysis suggests that it is on a downtrend, with some traders predicting a significant price drop to around $17 by the end of the day.

Generated by AI

Topics

Of the messages about NAOV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	55.9%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	44.1%

Earnings· Aug 16

NanoVibronix, Inc. (NAOV) reported a significant improvement in quarterly earnings, with EPS rising from -$0.20 to -$0.01.
The company's quarterly earnings exceeded market expectations, with a beat of $0.09 EPS compared to the expected -$0.10 EPS.
NAOV's strong earnings were driven by revenue growth of 18% and a cash position of $6 million, with no long-term debt.

Announcements· Sep 15

NanoVibronix, Inc. (NAOV) announces the grant of a new U.S. patent, further expanding its ENvue Medical subsidiary's intellectual property portfolio.
The patent covers proprietary systems for guiding the insertion of medical devices, such as feeding tubes, using electromagnetic positioning technology, improving real-time visualization and procedural accuracy.
The new patent strengthens NanoVibronix's intellectual property portfolio and reinforces competitive barriers in its target markets, with the company's CEO calling it a "significant milestone".

Technical Analysis· Sep 15

$NAOV broke out with a bang, volume surged, and RSI hit the skies, painting a bullish picture.
$NAOV shattered expectations with a technical breakout, volume surged along with RSI signals, and the chart is now green.
$NAOV is holding above $15 after a sharp pullback from $17, reclaiming trend and flagging just above support with VWAP, with a strong support level at $12.00.

Generated by AI

Community

Of the messages about NAOV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	51.42%
Newcomers	—	—	—	48.58%

Regulars· Sep 18

NanoVibronix has launched the "Oscar" training aid to accelerate the adoption of its ENvue system, potentially unlocking new revenue opportunities.
The "Oscar" platform is expected to transform naso-enteral training, a medical technology breakthrough that could have a significant impact on the company's future.
The launch of "Oscar" is a strategic move to increase the adoption of ENvue, which could lead to increased revenue for NanoVibronix.

Newcomers· Oct 8

The target price for $NAOV is $7.50-8.50, with an estimated upside potential of 15%-25% due to patent approvals, financing news, and enhanced liquidity.
The recent share price increase in $NAOV is primarily driven by the U.S. patent approval received by its subsidiary, ENVue Medical, and has reached $7.31, with a 19.44% surge.
The low float of $NAOV, at 862k, may be fueling the after-hours run, but there are no major news catalysts visible, indicating potential volatility ahead.

Generated by AI

NanoVibronix

Social

Nov 25

Sentiment

Bullish· Nov 25

Bearish· Sep 15

Topics

Earnings· Aug 16

Announcements· Sep 15

Technical Analysis· Sep 15

Community

Regulars· Sep 18

Newcomers· Oct 8

News

ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

ENvue Medical completes US manufacturing transition

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

Also Discussed

NanoVibronix, Inc.

Company Information

Location

News

ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

ENvue Medical completes US manufacturing transition

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

Also Discussed

Social

Nov 25

Sentiment

Bullish· Nov 25

Bearish· Sep 15

Topics

Earnings· Aug 16

Announcements· Sep 15

Technical Analysis· Sep 15

Community

Regulars· Sep 18

Newcomers· Oct 8